首页> 外文期刊>Palliative medicine >Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
【24h】

Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.

机译:入姑息治疗室时不适当使用大剂量的透皮芬太尼。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A retrospective study was conducted to determine the patterns of strong opioid use in patients admitted to a hospice inpatient unit, with special attention to the use of the transdermal fentanyl patch. This study was conducted to validate or negate the subjective feeling that many patients, treated at admittance with the fentanyl patch, received inappropriately high doses compared to patients treated with oral or parenteral opioids. The case notes of 1154 patients were reviewed and data collected on age, sex, diagnosis, care settings, opioid form and dose on referral, maximal dose during admission and opioid use during the last 24 hours of their life. At admission opioids had been prescribed for 47% of patients. Thirty-two percent of these patients received oral morphine. The median dose at admission of those patients was 60 mg (oral morphine equivalent (OME)). Thirty-six percent of the patients on opioids were using the fentanyl patch. The median dose at admission was triple that of the orally treated patients (median 180 mg OME). In the 199 patients using transdermal fentanyl at admission, in most patients the dose of the patch was gradually diminished and finally stopped in 58% of patients. Only 83 kept it until the last 24 hours. We would like to draw attention to the fact that (sometimes inappropriately) high doses of fentanyl were used at admission, probably due to lack of knowledge of the relative strength of the opioid involved and to the failure to recognize the phenomenon of opioid-induced hyperalgesia. In addition, in our experience the long action of the patch can be a disadvantage during the last days and weeks of life, due to the difficulty of dose adjustment and the risk for toxicity.
机译:进行了一项回顾性研究,以确定在临终关怀医院住院的患者中强烈使用阿片类药物的方式,尤其要注意透皮芬太尼贴剂的使用。进行这项研究是为了验证或否定主观感觉,与口服或胃肠外阿片类药物治疗的患者相比,许多接受芬太尼贴剂治疗的患者接受了不适当的高剂量。审查了1154例患者的病例记录,并收集了有关年龄,性别,诊断,护理环境,阿片类药物的形式和转诊剂量,入院期间的最大剂量以及生命中最后24小时内使用阿片类药物的数据。入院时已为47%的患者开了阿片类药物。这些患者中有32%接受了口服吗啡。这些患者入院时的中位剂量为60 mg(口服吗啡当量(OME))。 36%的阿片类药物患者使用芬太尼贴剂。入院时的中位剂量为口服治疗患者的中位剂量的三倍(中位数为180 mg OME)。在入院时使用透皮芬太尼的199位患者中,大多数患者中贴剂的剂量逐渐减少,并最终在58%的患者中停止使用。直到最后24小时为止,只有83个保留它。我们想提请注意以下事实:入院时(有时不适当)使用大剂量的芬太尼,可能是由于对所涉及的阿片类药物的相对强度缺乏了解以及未能识别出阿片类药物引起的痛觉过敏现象。另外,根据我们的经验,由于剂量调整的困难和毒性的风险,贴剂的长效作用在生命的最后几天和几周内可能是不利的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号